Institute of Molecular Physiology and Genetics
>
Possible correlations between expression/activity of various proteins/enzymes markers and incidence of myelodysplastic syndrome (MDS) and its development to acute myeloid leukemia (AML) in samples from patients treated and untreated with Lenalidomide, as well as Lenalidomide’s effects on expression/activity of some markers using the leukemic cell lines.
function goBack() { window.history.go(-1); }
Principal investigator: Albert Breier (Contract with the Celgene company)Duration: October 2009 – December 2014Coordinating institution: Institute of Molecular Physiology and Genetics, SAS, Bratislava |
Publications: |
 |
Messingerova L, Jonasova A, Barancik M, Polekova L, Seres M, Gibalova L, Breier A, Sulova Z. Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome. Gen Physiol Biophys. 34 (2015) 399–406 |
| Messingerova L, Barancik M, Jonasova A, Seres M, Gibalova L, Breier A, Sulova Z: Effect of lenalidomide therapy on the levels of P-glycoprotein, MRP and matrix matalloproteinases in patients with 5q-myelodysplastic syndrome. In Leukemia Research, 37 (2013) supplement 1, S108-S109. |